Cutaneous T Cell Lymphoma News and Research

RSS

Anti-cancer drug shows promise in treating brain injuries after stroke

A study by the Institut de Neurociències of the UAB (INc-UAB) demonstrates in animal models the benefits of vorinostat after having suffered a stroke.

28 Feb 2024

Creating New Targeted Antibacterial Products to Help Tackle Antimicrobial Resistance

We speak to Matthew Dunne, Director for Drug Discovery at Micreos Pharmaceuticals, about the importance of creating new targeted antibacterial products.

22 Nov 2022

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.

17 Oct 2022

Anonymous $5.75 million gift will enable UVA to fight against rare blood cancers

A gift of more than $5.75 million from anonymous donors will allow UVA Cancer Center to speed the development of new treatments for rare blood cancers and provide more patients with these cancers access to cutting-edge clinical trials.

29 Aug 2022

Deadly subtype of T-cell lymphoma harbors unique mutations

An especially deadly subtype of T-cell lymphoma is distinguished by unique mutations in a specific protein signaling pathway, according to a study published in the journal Blood.

7 Oct 2021

PD1 gene deletions associated with worse prognoses of cutaneous T-cell lymphomas

Immunohistochemistry staining showing PD1 expression on tumor cells in a skin biopsy from a cutaneous T-cell lymphoma patient.

5 Aug 2021

Cancer risk in psoriatic patients

A new study published in February 2020 in the journal JAMA Dermatology reports that there is a 21% increased risk of cancer in patients with psoriasis, but not with psoriatic arthritis alone.

19 Feb 2020

Pre-existing anticancer drug could help treat common form of heart failure

When it comes to finding new treatments for disease, reinventing the wheel is not always necessary - drugs already in use for other conditions may do the job.

29 Jan 2020

Discovery could unlock new ways to treat a rare blood disease

A cancer researcher at the University of Alberta has made a discovery that could unlock new ways to treat a rare blood disease.

27 Jan 2020

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.

22 Jan 2020

Researchers analyze precise mechanism of binding reaction in PUVA therapy

The term 'PUVA' stands for 'psoralen' and 'UV-A radiation'. Psoralens are natural plant-based compounds that can be extracted from umbelliferous plants such as giant hogweeds.

21 Aug 2019

GW Cancer Center selected as first global clinical trial site for high risk cutaneous squamous cell carcinoma

Under the leadership of Vishal A. Patel, MD, FAAD, FACMS, director of the Cutaneous Oncology Program at the George Washington University Cancer Center, the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.

3 Aug 2019

New drugs on PBS for Parkinson's, MND and Cutaneous T cell lymphoma

Under Australia's Pharmaceutical Benefits Scheme (PBS), soon many of the rare diseases and their treatments are set to become cheaper.

21 Mar 2019

New forms of older anti-cancer agent appear to enhance immune response to fight melanoma

Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they developed appear to enhance the immune system's ability to fight melanoma in mice.

20 Feb 2019

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.

16 Jun 2016

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Penn study forms basis for new treatment approaches for Sezary syndrome

Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to investigators from the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015